Table 17: Daily Hunger Scores Change from Baseline at 1 Year in IMCIVREE-Treated Patients Aged 12 Years with Obesity due to POMC, PCSK1, or LEPR Deficiency in Trials 3 and 4 with Available Hunger Data Hunger scores generally worsened during the double-blind, placebo withdrawal period among those patients who had experienced an improvement from baseline, and scores improved when IMCIVREE was reinitiated
They slow gastric emptying, increase feelings of fullness, and act on appetite centers in the brain, which leads to an overall calorie deficit
Mild effects may include
Eli Lilly, Novo Nordisks main rival in diabetes and weight loss drugs, still holds its patent in Canada for Mounjaro and Zepbound and faces no imminent patent expiry here
Timing Baseline Marker Comprehensive metabolic panel (CMP) Why it matters Reviews liver enzymes, kidney markers, electrolytes, and glucose in one broad safety panel
Need private label